Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc has demonstrated a robust clinical pipeline focused on addressing inherited retinal diseases (IRDs) and other retinal disorders, which positions the company favorably within the ophthalmic biopharmaceutical sector. Recent efficacy data indicates significant patient-reported functional benefits and sustained visual improvements, with a notable increase in the percentage of patients achieving substantial gains in near vision and other key metrics post-treatment. Furthermore, the positive regulatory signals received from the EMA regarding accelerated pathways suggest strong potential for market entry and revenue generation in the near future.

Bears say

Opus Genetics Inc. reported a decrease in research and development expenses for the quarter, totaling $6.4 million, down from $9.0 million a year prior, indicating potential challenges in sustaining R&D efforts amidst ongoing financial losses. The company has consistently incurred significant losses since its inception, raising concerns about its financial viability and long-term sustainability in the competitive biopharmaceutical market. Additionally, the presence of emerging therapies targeting similar inherited retinal diseases poses a substantial risk to market penetration and pricing, further complicating the company’s growth prospects in a challenging landscape.

Opus Genetics (IRD) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.